EP 28

Eroom's Law

The pharmaceutical industry is facing a paradox: despite scientific progress, drug discovery is getting slower and more expensive. This episode explores the challenges and innovations in the industry, including the role of intellectual property rights, the impact of pandemics, and the need for new antibiotics. The industry's economic footprint is also significant, contributing to global GDP and creating jobs.

pharmaceutical industrydrug discoveryinnovationintellectual property rightsglobal health

play_arrowListen to episode

Key Concepts

Eroom's Law

Describes the trend of increasing costs and decreasing productivity in drug discovery
Suggests that the industry is facing significant challenges in developing new medicines

Pharmaceutical Innovation

Involves the development of new medicines and treatments
Requires significant investment and risk-taking

Intellectual Property Rights

Essential for incentivizing innovation and investment in the industry
Include patents and regulatory data protection

Collaborative Ecosystem

Involves public sector research institutions, nonprofits, academic institutions, biotech companies, and funding sources
Critical for advancing pharmaceutical innovation

Global Health Challenges

Include the threat of future pandemics, antimicrobial resistance, and gaps in the pipeline for diseases affecting poorer countries
Require significant investment and innovation to address

Episode Summary

check_circleEroom's Law suggests that drug discovery is getting slower and more expensive despite scientific progress
check_circleThe pharmaceutical industry is a high-stakes scientific drama with enormous investment needed and complex journey from lab idea to patient
check_circleThe industry has a low success rate, with only 1-2 compounds out of 10,000 making it to market approval
check_circleCompanies decide which compounds are worth the gamble through a mix of cutting-edge science, predictive modeling, and risk tolerance
check_circleThe journey from idea to patient is long and complex, involving early discovery screening, preclinical research, clinical development, and regulatory review
check_circleThe industry is a collaborative ecosystem involving public sector research institutions, nonprofits, academic institutions, biotech companies, and funding sources
check_circleIntellectual property rights, such as patents and regulatory data protection, are essential for incentivizing innovation and investment
check_circleThe industry has made significant progress in transforming lives, including the development of vaccines, antibiotics, and treatments for diseases like HIV and cancer
check_circleHowever, there are still significant challenges, including the threat of future pandemics, antimicrobial resistance, and gaps in the pipeline for diseases affecting poorer countries
check_circleThe industry has a massive economic footprint, contributing to global GDP and creating jobs, and investment in health innovation can yield significant returns

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.